302 related articles for article (PubMed ID: 22329103)
1. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
Grave S
Aust Nurs J; 2011 Dec-2012 Jan; 19(6):30-3. PubMed ID: 22329103
[TBL] [Abstract][Full Text] [Related]
2. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
Khoo CW; Lip GY
Expert Opin Pharmacother; 2010 Mar; 11(4):685-7. PubMed ID: 20105114
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran in clinical practice.
Nagarakanti R; Ellis CR
Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Siddiqui FM; Qureshi AI
Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
[TBL] [Abstract][Full Text] [Related]
7. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
Dzeshka MS; Lip GY
Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
Belavic JM
Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
[No Abstract] [Full Text] [Related]
10. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Ma TK; Yan BP; Lam YY
Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
[TBL] [Abstract][Full Text] [Related]
13. Should dabigatran replace warfarin for stroke prevention in AF?
Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
[TBL] [Abstract][Full Text] [Related]
14. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
16. [The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
Vojácek J
Vnitr Lek; 2009 Nov; 55(11):1085-8. PubMed ID: 20017441
[TBL] [Abstract][Full Text] [Related]
17. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran: will it change clinical practice?
Wartak SA; Bartholomew JR
Cleve Clin J Med; 2011 Oct; 78(10):657-64. PubMed ID: 21968472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]